Galectin Therapeutics Inc.

NASDAQ
GALT
paper.types.company
Rentabilité sur six mois: +4.58%
Rendement en dividendes: 0%
Secteur: Healthcare

1.37 $

0 $ -0%
0.8406 $
3 $

paper.min_max_per_year

Calendrier des promotions Galectin Therapeutics Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2002-09-09
ISIN
US3632252025
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV -0.665 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -205.92 0
ROE 57.62 10
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -2.56 10
Debt/Ratio 6.07 0
Debt/Equity -1.17 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 77.22 8
Rentabilité EPS, % 83.09 9
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.37 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.32 $ 0 $ 0 $ 3.79 % 0 % 0 %
common.calendar.number_days.30d 1.28 $ 1.32 $ 1.37 $ 7.03 % 0 % 0 %
common.calendar.number_days.90d 1.35 $ 1.24 $ 1.57 $ 1.48 % 0 % 0 %
common.calendar.number_days.180d 1.31 $ 1.1 $ 1.77 $ 4.58 % 0 % 0 %
common.calendar.number_days.1y 2.86 $ 0.8406 $ 3 $ -52.1 % 0 % 0 %
common.calendar.number_days.3y 1.93 $ 0.8406 $ 4.2 $ -29.02 % 0 % 0 %
common.calendar.number_days.5y 2.56 $ 0.8406 $ 5.1 $ -46.48 % 0 % 0 %
common.calendar.number_days.10y 0.51 $ 0.51 $ 9.16 $ 268.63 % 0 % 0 %
common.calendar.number_days.ytd 1.25 $ 1.1 $ 1.77 $ 9.6 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Joel Lewis President, CEO & Director 907.72k 1970 (55 années)
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 521.47k 1967 (58 années)
Robert Tritt General Counsel N/A
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development N/A
Ms. Beth Knowles Executive Assistant & Officer Manager N/A
Mr. Khurram Jamil M.D. Chief Medical Officer

Informations sur l'entreprise

Adresse: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://galectintherapeutics.com